Skip to main content

Search

Show all results for

Home

Person

Philippe Guillaume Coune

This person is no longer with EPFL

About
Privacy
Disclaimer

Copyright © 2025 EPFL, all rights reserved

Graph Chatbot

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Related publications (5)

Please note that this is not a complete list of this person’s publications. It includes only semantically relevant works. For a full list, please refer to Infoscience.

Machine learning predictions of MHC-II specificities reveal alternative binding mode of class II epitopes

Florence Pojer, George Coukos, Kelvin Ka Ching Lau, Amédé Noredine Larabi, Julien Racle, David Gfeller, Philippe Guillaume Coune, Marta Andreia Da Silva Perez, Alexandre Harari

CD4+T cells orchestrate the adaptive immune response against pathogens and cancer by recognizing epitopes presented on class II major histocompatibility complex (MHC-II) molecules. The high polymorphism of MHC-II genes represents an important hurdle toward ...

CELL PRESS2023

Parkinson's Disease: Gene Therapies

Patrick Aebischer, Bernard Schneider, Philippe Guillaume Coune

With the recent development of effective gene delivery systems, gene therapy for the central nervous system is finding novel applications. Here, we review existing viral vectors and discuss gene therapy strategies that have been proposed for Parkinson's di ...

Cold Spring Harbor Lab Press, Publications Dept2012

An in vivo ultrahigh field 14.1 T (1) H-MRS study on 6-OHDA and α-synuclein-based rat models of Parkinson's disease: GABA as an early disease marker

Rolf Gruetter, Patrick Aebischer, Bernard Schneider, Mélanie Craveiro, Philippe Guillaume Coune, Meret Gaugler

The detection of Parkinson's disease (PD) in its preclinical stages prior to outright neurodegeneration is essential to the development of neuroprotective therapies and could reduce the number of misdiagnosed patients. However, early diagnosis is currently ...

Wiley-Blackwell2013